Skip to main content
. Author manuscript; available in PMC: 2015 Oct 21.
Published in final edited form as: Clin Pharmacol Ther. 2008 May 28;85(2):155–163. doi: 10.1038/clpt.2008.95

Table 4. PcR primer sequences.

Polymorphism Forward 5′-3′ Reverse 5′-3′
SLCO1B3 334T>G CATGGTCTTTG
AGGGAAGGT
AGGAAATATACTC
CATTTCTCTATGC
SLCO1B3 439A>G CAGCGGTTCAA
ATAAAGGAGA
TGTGTTGTTTA
AGAATCGACTGC
SLCO1B3 699G>A AAAAGCATGTTA
AATGAAAACCA
GGAAGAATGG
TGTCCTGCAC
SLCO1B3 767G>C ACATTTGGTTTA
CTTTCTTCATCTAT
AATCCTCTT
CCCCTTTTTAT
SLCO1B3 1559A> GGGAGCTATTT
TGCCTTCAC
TGTCAATCAGT
GTGTGCCTTA
SLCO1B3 1679T>C GGGAGCTATT
TTGCCTTCAC
TGTCAATCAGT
GTGTGCCTTA
CYP3A4 −392A>G TGGGATGAATT
TCAAGTATTTTG
CAGATAAGGG
AAAGAGAGGC
CYP3A5 6986A>G CCTGCCTTCAA
TTTTTCACTG
GCAATGTAGGA
AGGAGGGCT
ABCB1 1236C>T TGAACAGTCAG
TTCCTATATCCTG
TGTGCAATGT
GACTGCTGAT
ABCB1 2677G>T/A GCAGGCTATAG
GTTCCAGGCT
TGAGGAATGG
TTATAAACACAT
ABCB1 3435C>T TCACAGTAACT
TGGCAGTTTCAG
ACTATAGGCC
AGAGAGGCTG
ABCC2 −1019A>G TCCTTTGACTC
CTTTCCTTCTTT
GCCTCAGCTT
CCTGAGTAGC
*GGATTTTGACA
ATTGCAT TCC
*ACTACAGGC
ACATGCCAACA
ABCC2 −24C>T TGTCCTTAGGAAA
ATGAAAGACTG
TTGCACATCTA
ACATTTCTGGTT
*ATTTGTTGGCC
AGCTCTGTT
*TCTTGTTGG
TGACCACCCTA
ABCC2 1249G>A GGGCAAAGAA
GTGTGTGGAT
CAGCAGAGCA
AGATGGAAGA
*GGAGCACAT
CCTTCCATTGT
*TTGCCCAAAC
TCCCATTAAG
ABCC2 IVS26 −34T>C CATGATTCCG
TCCTCTGCTT
ACCTCATTTTC
CACTTTTGTGT
*TTCCGTCCTC
TGCTTTCTGT
*CAACAGCCAC
AATGTTGGTC
ABCC2 3972C>T GGAACTTTCCA
AAAGTGCAAG
GTGTGATCC
CTGGCTGCTAT
*TAGCTGGGAC
ACTGCTACCC
*CTTTCCCTC
CATCCAAATGA
ABCC2 4544G>A GGCACCCTT
TGTAAACCAAT
TGCACCTATTT
GCATCACCA
*GATGTGTGTA
GCTGTGGCTCA
*CAGAAATGAA
AGGCAAAGGAA
*

Nested.

HHS Vulnerability Disclosure